APX2009 Intravitreal Formulation

APX2009 is a second-generation preclinical product candidate analog of APX3330. In mouse models of retinal neovascularization, APX2009 was effective in decreasing lesion size as well as improved efficacy against the Ref-1 target compared to APX3330. An intravitreal formulation could present itself as an alternative to APX3330’s oral formulation (as published in the Journal of Pharmacology and Experimental Therapeutics).

Product Candidate Indication Development Stage Anticipated Milestones
Preclinical Phase 1 Phase 2 Phase 3

Partnering-Focused Development

APX2009 Intravitreal DME, Wet Age-Related Macular Degeneration (wAMD)
Preclinical in progress
Phase 1 not started
Phase 2 not started
Phase 3 not started
Next Steps: IND enabling studies (with partner funding)

Are We Seeing Eye to Eye?

Interested in a partnership to in-license our clinical drug candidates?

Contact Us

Read Our Posters & Publications

We are dedicated to publishing the results of APX2009 studies in peer-reviewed medical journals.

Browse Posters & Publications